Absence of a CD34- hematopoietic precursor population in recipients of CD34+ stem cell transplantation

被引:8
|
作者
Kato, S
Ando, K
Nakamura, Y
Muguruma, Y
Sato, T
Yabe, H
Yabe, M
Hattori, K
Yasuda, Y
Hotta, T
机构
[1] Tokai Univ, Sch Med, Dept Hematol, Isehara, Kanagawa 25911, Japan
[2] Tokai Univ, Sch Med, Dept Pediat, Isehara, Kanagawa 25911, Japan
[3] Tokai Univ, Sch Med, Res Ctr Cell Transplantat, Isehara, Kanagawa 25911, Japan
基金
日本学术振兴会;
关键词
CD34-enriched transplantation; CD34(-) precursor population; hematopoietic stem cells; bone marrow stroma cells;
D O I
10.1038/sj.bmt.1703186
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The purified CD34(+) cell fraction has been used for hematopoietic stem cell transplantation since they were demonstrated to have long-term reconstituting ability. Therefore, the potential effects of CD34(-) stem cells on the clinical course have been a major concern in recipients of CD34(+)-selected transplantation. To address this concern, we used an in vitro assay to determine whether transplant recipients have CD34- precursor population. Lin(-)CD34(-) cells were isolated from bone marrow cells in 11 transplant recipients including four CD34-selected transplantations, six standard bone marrow transplantations, and one T cell-depleted marrow transplantation. The frequency of the Lin-CD34- population in four CD34-enriched transplantation recipients was not different from those of normal donors or recipients of other modes of transplantation: 0.96 +/- 1.01% (mean +/- s.d., n = 4), 0.45 +/- 0.16% (n = 6), and 0.66 +/- 0.59% (n = 7), respectively. However, the Lin-CD34- population obtained from the recipients of CD34-enriched transplantation acquired neither CD34 expression nor colony-forming activity after 7 days of culture, whereas the cells from all the normal individuals and standard BMT recipients were able to differentiate into CD34+ cells accompanied by the emergence of colony-forming activity. We conclude that recipients of CD34-enriched transplantation appear to have defects in their CD34(-) precursor population. The clinical significance of these defects will be determined in a life-long follow-up of these patients.
引用
下载
收藏
页码:587 / 595
页数:9
相关论文
共 50 条
  • [31] Enumeration of CD34+ hematopoietic precursor cells:: Current status
    Reis, MD
    TRANSPLANTATION PROCEEDINGS, 1999, 31 (07) : 2970 - 2972
  • [32] Isolation of CD34- and CD34+ Leukemia Stem Cells from Acute Myeloid Leukemia Blasts Using CD200
    Ho, Jenny M.
    Dobson, Stephanie M.
    McLeod, Jessica
    Voisin, Veronique
    Murison, Alex
    Kennedy, James
    Zandi, Sasan
    Eppert, Kolja
    Minden, Mark D.
    Lupien, Mathieu
    Dick, John E.
    Wang, Jean C. Y.
    BLOOD, 2018, 132
  • [33] CD34+ CELL DOSE OF MARROW GRAFT PREDICTS OUTCOMES IN PEDIATRIC RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
    Suliman, Ali Y.
    Wells, Joseph R.
    Sunkara, Anusha
    Kang, Guolian
    Hughes, Carlton
    Alloush, Lina
    Hale, Jennifer
    Qudeimat, Amr
    Akel, Salem
    Triplett, Brandon
    Srinivasan, Ashok
    PEDIATRIC BLOOD & CANCER, 2019, 66
  • [34] Both CD34+ and CD34- cells have the potential to differentiate to natural killer cells
    Lu, J
    Patrene, KD
    Herberman, RB
    Boggs, SS
    EXPERIMENTAL HEMATOLOGY, 1998, 26 (08) : 773 - 773
  • [35] CD34+ selected grafts in pediatric stem cell transplantation.
    Yu, LC
    Palm, S
    Leiva, L
    BLOOD, 2000, 96 (11) : 326B - 326B
  • [36] Spontaneous apoptosis in CD34+ AND CD34- subpopulations of acute myeloid leukemia patients.
    Bontje, PM
    Ossenkoppele, GJ
    Beelen, RHJ
    vandeLoosdrecht, AA
    Broekhoven, MG
    Schuurhuis, GJ
    BLOOD, 1997, 90 (10) : 3469 - 3469
  • [37] CD34+selected autologous peripheral blood stem cell transplantation (CD34+/ASCT) for multiple sclerosis
    Carreras, E
    Saiz, A
    Marín, P
    Martínez, C
    Rovira, M
    Villamor, N
    Aymerich, M
    Lozano, M
    Fernández-Avilés, F
    Urbano-Ispizua, A
    Berenguer, J
    Arbizu, T
    Montserrat, E
    Graus, F
    BONE MARROW TRANSPLANTATION, 2003, 31 : S16 - S16
  • [38] Autologous CD34+selected peripheral blood stem cell transplantation (CD34+/PBSCT) for multiple sclerosis
    Carreras, E
    Saiz, A
    Graus, F
    Marín, P
    Martínez, C
    Rovira, M
    Urbano-Ispizua, A
    Arbizu, T
    Casanova, B
    Mercader, JM
    Mazzara, R
    Merino, A
    Tolosa, E
    Montserrat, E
    BLOOD, 1999, 94 (10) : 398B - 398B
  • [39] Prevalence of CD7+ cells in CD34-/Lin- human hematopoietic stem cell fractions
    Rohde, E
    Lanzer, G
    Linkesch, W
    Strunk, D
    TRANSFUSION, 2003, 43 (09) : 52A - 53A
  • [40] Prediction of CD34+ cell yield in hematopoietic cell products from children by peripheral blood CD34+ cell counts
    Rujkijyanont, Piya
    Hipps, John
    Gan, Kwan
    Yang, Jie
    Wang, Chong
    Geiger, Terrence L.
    Eldridge, Paul W.
    Leung, Wing
    CYTOTHERAPY, 2012, 14 (04) : 473 - 482